文献速递乳腺癌

遗传易感女性晚发性乳腺癌风险研究

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
PubMed 文献 · J Clin Oncol · 2021-07-22

该研究基于26,707例65岁以上女性(51.5%乳腺癌患者,48.5%未患病)检测胚系易感基因致病性变异(PV),发现乳腺癌患者PV频率为3.18%,未患病女性为1.48%。BRCA1、BRCA2、PALB2和CHEK2的PV与乳腺癌风险升高相关(OR=2.9-4.0),BRCA1、BRCA2和PALB2 PV携带者终生乳腺癌风险≥15%。

要点

  • 65岁以上乳腺癌患者胚系PV频率为3.18%,未患病女性为1.48%。
  • 三阴性或ER阴性乳腺癌患者应接受基因检测。
  • 65岁以上BRCA1/2 PV携带者应考虑MRI筛查,PALB2和CHEK2或可考虑。

核心结论

  • 所有三阴性或ER阴性乳腺癌患者应接受基因检测。
  • 65岁以上BRCA1/2 PV携带者及可能的PALB2和CHEK2 PV携带者应考虑MRI筛查。

研究设计与样本

  • 基于人群的横断面研究,纳入26,707例65岁以上女性,其中51.5%为乳腺癌患者,48.5%为未患病女性,检测胚系易感基因PV。

主要发现

  • 乳腺癌患者PV频率为3.18%,未患病女性为1.48%。
  • BRCA1、BRCA2和PALB2 PV在ER阴性乳腺癌中占3.42%,ER阳性中占1.0%,三阴性中占3.01%。
  • 无一级亲属乳腺癌史的女性PV频率较低。
  • CHEK2、PALB2、BRCA2和BRCA1的PV与乳腺癌风险升高相关(OR=2.9-4.0)。
  • BRCA1、BRCA2和PALB2 PV携带者剩余终生乳腺癌风险≥15%。

关键数值与推荐

  • 65岁以上乳腺癌患者PV频率3.18%,未患病女性1.48%。
  • ER阴性乳腺癌中BRCA1/2/PALB2 PV频率3.42%,ER阳性1.0%,三阴性3.01%。
  • CHEK2、PALB2、BRCA2、BRCA1 PV与乳腺癌风险OR=2.9-4.0。
  • BRCA1、BRCA2、PALB2 PV携带者剩余终生风险≥15%。

临床怎么用

  • 对65岁以上三阴性或ER阴性乳腺癌患者进行基因检测。
  • 对65岁以上BRCA1/2 PV携带者考虑MRI筛查,PALB2和CHEK2 PV携带者可考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prevalence of germline pathogenic variants (PVs) in established breast cancer predisposition genes in women in the general population over age 65 years is not well-defined. However, testing guidelines suggest that women diagnosed with breast cancer over age 65 years might have < 2.5% likelihood of a PV in a high-penetrance gene. This study aimed to establish the frequency of PVs and remaining risks of breast cancer for each gene in women over age 65 years. METHODS: A total of 26,707 women over age 65 years from population-based studies (51.5% with breast cancer and 48.5% unaffected) were tested for PVs in germline predisposition gene. Frequencies of PVs and associations between PVs in each gene and breast cancer were assessed, and remaining lifetime breast cancer risks were estimated for non-Hispanic White women with PVs. RESULTS: The frequency of PVs in predisposition genes was 3.18% for women with breast cancer and 1.48% for unaffected women over age 65 years. PVs in BRCA1, BRCA2, and PALB2 were found in 3.42% of women diagnosed with estrogen receptor (ER)-negative, 1.0% with ER-positive, and 3.01% with triple-negative breast cancer. Frequencies of PVs were lower among women with no first-degree relatives with breast cancer. PVs in CHEK2, PALB2, BRCA2, and BRCA1 were associated with increased risks (odds ratio = 2.9-4.0) of breast cancer. Remaining lifetime risks of breast cancer were ≥ 15% for those with PVs in BRCA1, BRCA2, and PALB2. CONCLUSION: This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Boddicker NJ, Hu C, Weitzel JN, et al. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. J Clin Oncol. 2021. PMID: 34292776. doi:10.1200/JCO.21.00531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。